<DOC>
	<DOCNO>NCT00303264</DOCNO>
	<brief_summary>`` Functional dyspepsia '' define loosely `` pain discomfort center upper abdomen . '' The symptom also include fullness , early satiety , bloating , belching , nausea , retch vomit . These symptom may present without co-existence symptom heartburn gastroesophageal reflux disease ( GERD ) . Functional dyspepsia diagnosis exclusion disease state , ulcer , cancer , etc . rule source pain unknown . The standard care patient present dyspeptic symptom proton pump inhibitor ( PPI ) , regardless whether patient 's symptom include acid-related condition , e.g. , heartburn , GERD , etc . Although PPI treatment yield success patient , significant population patient whose dyspeptic symptom adequately treat PPI 's alone . The purpose study evaluate use dexloxiglumide treatment symptom functional dyspepsia patient whose dyspeptic symptom treat adequately PPI 's .</brief_summary>
	<brief_title>The Safety Efficacy Dexloxiglumide Relief Symptoms Functional Dyspepsia .</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Be male female , 18 75 year age , inclusive . Must understand English able follow instruction complete diary questionnaire . At time Screening , pain and/or discomfort upper abdomen least one day week last month . At time Screening , least one symptom FD least one day week last month . Have know hypersensitivity dexloxiglumide , PPI , aluminum/magnesiumcontaining antacid Have history organic disease , structural biochemical , gastrointestinal system cause dyspepsia . Have active irritable bowel syndrome ( CIBS , altIBS , DIBS ) . Have finding lead clinical suspicion secondary cause dyspepsia , include endocrine , metabolic neurological disorder . Have body mass ( BMI ) value great 38 ( applies male female ) . Have enrol previous investigational study dexloxiglumide . Have receive treatment investigational drug within 30day period , 5 halflives , whichever longer , prior study entry . Use dependence `` prohibit '' medication study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>functional dyspepsia</keyword>
	<keyword>cholecystokinin</keyword>
	<keyword>CCK</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>intestinal transit</keyword>
	<keyword>GI motility</keyword>
	<keyword>bloating</keyword>
	<keyword>upper GI discomfort</keyword>
	<keyword>upper GI</keyword>
	<keyword>early satiety</keyword>
	<keyword>nausea</keyword>
	<keyword>belching</keyword>
	<keyword>retch</keyword>
	<keyword>vomit</keyword>
	<keyword>GERD</keyword>
</DOC>